Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.

Eliasson DG, Helgeby A, Schön K, Nygren C, El-Bakkouri K, Fiers W, Saelens X, Lövgren KB, Nyström I, Lycke NY.

Vaccine. 2011 May 23;29(23):3951-61. doi: 10.1016/j.vaccine.2011.03.090. Epub 2011 Apr 8.

PMID:
21481325
2.

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.

Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10.

PMID:
18243429
3.
4.

CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.

Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N.

J Immunol. 2001 Sep 15;167(6):3398-405.

5.

The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.

Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lövgren K, Schön K, Mowat A, Lycke NY.

J Immunol. 2006 Mar 15;176(6):3697-706.

6.

The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Andersen CS, Dietrich J, Agger EM, Lycke NY, Lövgren K, Andersen P.

Infect Immun. 2007 Jan;75(1):408-16. Epub 2006 Oct 30.

7.

CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization.

Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam GB, Lycke NY.

J Gen Virol. 2008 Dec;89(Pt 12):2954-64. doi: 10.1099/vir.0.2008/005470-0.

PMID:
19008380
8.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

9.

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

De Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W.

Vaccine. 2006 Jan 30;24(5):544-51. Epub 2005 Aug 31.

PMID:
16169634
10.

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.

Vaccine. 2006 May 1;24(18):3990-4006. Epub 2005 Dec 27.

PMID:
16516356
11.

The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.

Akhiani AA, Stensson A, Schön K, Lycke N.

Scand J Immunol. 2006 Feb;63(2):97-105.

PMID:
16476008
14.

Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.

Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.

J Immunol. 2010 Sep 1;185(5):2935-41. doi: 10.4049/jimmunol.1000589. Epub 2010 Jul 30.

15.

Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.

Nedrud JG, Bagheri N, Schön K, Xin W, Bergroth H, Eliasson DG, Lycke NY.

PLoS One. 2013 Dec 31;8(12):e83321. doi: 10.1371/journal.pone.0083321. eCollection 2013.

16.

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Löwenadler B, Lycke N, Jou WM, Saelens X.

Vaccine. 2006 Nov 10;24(44-46):6597-601. Epub 2006 Jun 12.

PMID:
16814430
17.

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.

Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27.

PMID:
20195654
18.
20.

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.

Cunningham KA, Carey AJ, Lycke N, Timms P, Beagley KW.

J Reprod Immunol. 2009 Jul;81(1):34-8. doi: 10.1016/j.jri.2009.04.002. Epub 2009 Jun 6.

PMID:
19501917
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk